RTTR - Ritter Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7600
-0.0499 (-6.16%)
As of 3:11PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.8099
Open0.8400
Bid0.76 x 1000
Ask0.80 x 800
Day's Range0.7500 - 0.8400
52 Week Range0.1830 - 4.0000
Volume42,804
Avg. Volume116,065
Market Cap4.358M
Beta (3Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)-3.08
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.67
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that it has passed the 50 percent enrollment point in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of LI, a study known as the “Liberatus” study. “We are pleased to have achieved this important milestone in study enrollment and we remain on track with our projected timeline for the completion of the Liberatus study in the second half of 2019,” said Andrew J. Ritter, CEO of Ritter Pharmaceuticals.

  • GlobeNewswirelast month

    Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced the closing on November 5, 2018 of its previously announced private placement of Series B convertible preferred stock and warrants to certain accredited investors, including two current institutional holders of our Series A convertible preferred stock, a key vendor and a member of the Company’s board of directors. The Company received gross proceeds of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

  • GlobeNewswirelast month

    Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that it has entered into a definitive agreement with certain accredited investors, including two current institutional holders of our Series A convertible preferred stock, a key vendor and a member of the Company’s board of directors, for a private placement of newly designated Series B convertible preferred stock and warrants.

  • GlobeNewswire2 months ago

    Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today presented additional data from its previously completed Phase 2b trial of RP-G28 exhibiting colonic microbiome adaptation and improved lactose tolerance. “These results are instrumental in understanding the mode of action and effectiveness of RP-G28 in increasing the abundance of gut microbes that are believed to rapidly metabolize lactose, which, in turn, improves lactose tolerance and mitigates the related gastric-based symptoms,” said M. Andrea Azcarate-Peril, Ph.D., Associate Professor of Medicine and Director the Microbiome Core at the University of North Carolina, Chapel Hill.

  • Ritter Pharmaceuticals Inc (NASDAQ:RTTR): Earnings To Drop Next Year, Is It A Long-Term Trend?
    Simply Wall St.11 months ago

    Ritter Pharmaceuticals Inc (NASDAQ:RTTR): Earnings To Drop Next Year, Is It A Long-Term Trend?

    The most recent earnings update Ritter Pharmaceuticals Inc’s (NASDAQ:RTTR) released in September 2017 revealed that losses became smaller relative to the prrior year’s level – great news for investors BelowRead More...

  • Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys
    Zackslast year

    Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys

    Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys